Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2025 14:16 ET | Source: HNL Lab Medicine

HNL Lab Medicine Begins Subtyping Positive Flu A Samples for H5N1 Avian Influenza

HNL Lab Medicine begins subtyping positive influenza A samples from hospitalized patients to detect H5N1 Highly Pathogenic Avian Influenza.
June 20, 2024 08:00 ET | Source: Cocrystal Pharma, Inc.

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1)...
March 19, 2024 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or...
July 20, 2023 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
October 18, 2022 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and...
July 14, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...
September 08, 2021 16:05 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside...
September 07, 2021 16:05 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd...
September 07, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will...
August 09, 2019 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

– Company continues to drive clinical and research programs forward to achieve multiple value-driving milestones– – Business development initiative underway with active discussions ongoing to secure...